Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases. Quench is targeting the pore-forming protein Gasdermin D, a central player in both pyroptosis and NETosis pathways that mediates the release of inflammatory cytokines, alarmins, DNA and NETs.
Headquarters | Cambridge, MA |
Website | www.quenchbio.com |
Pipeline | Preclinical |
@QuenchBio |